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Abstract
Overdiagnosis is the diagnosis of an abnormality that bears no substantial health hazard
and no benefit for patients to be aware of. Resulting mainly from the use of increasingly
sensitive screening and diagnostic tests, as well as broadened definitions of conditions
requiring an intervention, overdiagnosis is a growing but still largely misunderstood
public health issue. Fear of missing a diagnosis or of litigation, financial incentives or
patient’s need of reassurance are further causes of overdiagnosis. The main consequence
of overdiagnosis is overtreatment. Treating an overdiagnosed condition bears no benefit
but can cause harms and generates costs. Overtreatment also diverts health professionals
from caring for those most severely ill. Recognition of overdiagnosis due to screening is
challenging since it is rarely identifiable at the individual level and difficult to quantify
precisely at the population level. Overdiagnosis exists even for screening of proven
efficacy and efficiency. Measures to reduce overdiagnosis due to screening include
heightened sensitization of health professionals and patients, active surveillance and
deferred treatment until early signs of disease progression and prognosis estimation
through biomarkers (including molecular) profiling. Targeted screening and balanced
information on its risk and benefits would also help limit overdiagnosis. Research is
needed to assess the public health burden and implications of overdiagnosis due to
screening activity.
Keywords: Screening, Overdiagnosis, Overtreatment, Chronic diseases
Background
What is overdiagnosis?
Overdiagnosis was originally defined as the diagnosis of an inconsequential disease
(or pseudodisease), based on its clinicopathological characteristics, irrespective of its
host [1]. It was per se unrelated to life expectancy or mode of detection. Advances in,
and increasing use of, diagnostic and screening technologies, in a context where
chronic diseases prevail, has led to the early detection of more diseases during their
preclinical phase, i.e., before any symptom arises. This brought an epidemiological con-
cept of overdiagnosis: the diagnosis of a condition that would have remained indolent
in the patient’s lifetime if left undetected.
This concept ties overdiagnosis to screening and absence of gain in longevity. As
such, any patient screen-detected with a cancer or a precancerous lesion who eventu-
ally dies from competing mortality will be considered as an overdiagnosed case if (and
only if ) death occurs before clinical manifestation of this cancer (Fig. 1). Overdiagnosis
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is not limited to cancer and can occur with any other screened-detected condi-
tions, e.g., hypertension, diabetes, or osteoporosis. With this screening-related con-
cept, the earlier detection occurs before clinical presentation of a disease (lead
time), the greater the potential for overdiagnosis [2]. As overdiagnosis is a growing
but still largely misunderstood public health issue, we address hereafter the main
causes and consequences of overdiagnosis due to screening, and suggest ways to
reduce this undesirable screening effect.
What causes overdiagnosis?
Overdiagnosis has multiple causes (Table 1). The use of increasingly sensitive diagnos-
tic tests is a major source of overdiagnosis [3]. These tests lead to findings, incidentally
or not, of abnormalities of uncertain clinical hazard. Detection of non-life-threatening
prostate cancer by determination of prostate-specific antigen (PSA), of small papillary
thyroid cancer by ultrasonography, or of nonhypersecreting, benign adrenocortical ad-
enomas (so-called incidentaloma) by computed tomography (CT) are some classical ex-
amples [4–6]. Insufficient knowledge of the natural history of the screened disease, a
well-known pre-requisite to ensure the relevance of screening, also contributes to over-
diagnosis [7, 8]. For instance, growing evidence supports that different forms of cancers
are of variable progression rate, including indolent, regressive, slowly progressive and
aggressive tumours. This is at odds with the implicit assumption of a unique, orderly
and gradual progression of cancers on which screening is based [9]. Overdiagnosis can
also result from the detection of precancerous lesions even with screening methods of
Fig. 1 Overdiagnosis and lead time in screening (adapted from [2])
Table 1 Causes of overdiagnosis [14, 27]
• Screening and increasing sensitivity of diagnostic tests
• Incidental findings following screening or diagnostic tests
• Widening diagnosis criteria
• Confusion between risk and disease
• Physician’s fear of missing a disease or their patients expectations
• Financial incentives by pharmaceutical and diagnostic test industries
• Insufficient knowledge of the natural history of the disease
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established success, such as cervical intraepithelial neoplasia or polyp for cervical and
colorectal cancer.
A more subtle form of overdiagnosis is due to the tendency to broaden the definition
of conditions requiring treatment. This occurs for instance when screening targets a
risk factor for a disease blurring the boundary between health and disease [10]. For in-
stance, lowering the thresholds of blood pressure to define hypertension or pre-
hypertension increases the number of patients diagnosed with a condition requiring
follow-up and treatment. However, below a certain level of the risk factors, the associ-
ated absolute risk of disease is small and treatment bears little, if any, benefit [11]. This
is due to the loglinear relationship between risk factors such as blood pressure and risk
of associated diseases, which depends essentially on age for cardiovascular diseases
[12]. Hence, for an identical reduction in blood pressure, the resulting absolute risk of
disease reduction will be much smaller for individuals with blood pressure below a cer-
tain level compared with individuals with high level of blood pressure [13]. This leads
to overtreatment. Following the same logic, diabetes, pre-diabetes, or gestational dia-
betes as well as osteoporosis can also be overdiagnosed. Use of the relative rather than
the absolute risk magnifies the risk of these conditions and gives an overoptimistic im-
pression of the degree of risk reduction that could be expected from screening and
treating these conditions [11]. Fear of missing a diagnosis or of litigation, financial in-
centives or patient’s perceived need of reassurance are other causes of overdiagnosis
[14] (Table 1).
What are the consequences of overdiagnosis?
The main – and worst – consequence of overdiagnosis is overtreatment. By definition,
treating an indolent disease bears no benefit but can cause harms, generates costs and
wastes resources. This is particularly important for screening which, unlike other med-
ical interventions, targets healthy subjects, already exposed to other side effects of
screening, such as false-positive results [15, 16]. Notwithstanding, overtreatment shifts
pervasively the attention and utilization of some care away from those most severely ill.
Another under-recognised consequence of overdiagnosis is the psychological suffering
due to the unnecessary labelling of people with a lifelong diagnosis [17].
How to reduce overdiagnosis?
Once an abnormality is detected or a patient exceeds a set level of a risk factor, it is vir-
tually impossible and often unethical not to investigate and treat the patient, even if the
probability of overdiagnosis is high. This major challenge hinders the identifiability of
overdiagnosis at the individual level, which, in turn, hampers its recognition by clini-
cians and patients. However, potential measures to reduce overdiagnosis exist and de-
pend on the causes of overdiagnosis.
The fundamental precept primum non nocere must prevail against the broad “more is
better” attitudes and nearly blind beliefs in new, more diagnostically sensitive technolo-
gies. Physicians have limited training and suboptimal ability to adequately assess
screening benefit and overdiagnosis [18]. They should be provided with absolute mea-
sures of the risk reduction expected from screening, framed in an easy to understand
manner, and aimed at sharing the screening decision with their patients [19]. Increasing
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awareness of health professionals and patients about overdiagnosis should contribute
to fight against pressure to prescribe popular but inefficient screening tests and, to
some extent, against financial incentives from diagnostic and pharmaceutical industries
to perform them [20, 21].
As long as indolent lesions cannot be distinguished from aggressive ones at diagnosis,
screening will unavoidably result in some overdiagnosis [16]. Active surveillance, de-
ferred treatment until early signs of disease progression, and prognosis estimation
through biomarkers (including molecular) profiling are among our best prospects to
prevent overtreatment and to increase the benefit of screening [9, 22]. For instance, ap-
plication of a clinically validated genomic assay has enabled an individual risk stratifica-
tion of ductal carcinoma in situ (DCIS) of the breast and increased the number of
patients benefiting from conserving surgery [23]. Screening should also be limited to
tests/examinations and subpopulations for which the evidence-based benefit is strong,
and abide to the recommended interscreening interval. Targeted screening and bal-
anced information on its risk and benefits should help limit overdiagnosis. Comparative
studies of screening strategies taking into account specific biomarkers and other pa-
tients’ characteristics are needed for different diseases. While “personalized” screening
allows a better risk stratification of the patient and hence potentially prevent overtreat-
ment, it could generate overdiagnosis, notably through incidental findings, e.g., follow-
ing genome-wide sequencing [24].
It is essential to acknowledge that the balance between benefits, in terms of life saved,
and overdiagnosis, can be highly challenging to quantify, particularly for cancer screen-
ing, and contains a substantial level of uncertainty [2, 25]. Further, the perception of
this balance remains highly subjective, even for efficacious and cost-effective screening
interventions. For instance, some (patients, physicians, scientific experts, public health
authorities) may deem that 3 breast cancers overdiagnosed per life saved are well worth
recommending regular mammography screening for women aged 50 to 70 years,
whereas others may feel unconvinced by this balance [26].
Conclusions
While increasingly sensitive screening and diagnostic tests enable to detect many po-
tentially severe and socially relevant frequent chronic diseases at the earliest stages,
they concomitantly expand the disease reservoir of subclinical conditions from which
overdiagnosis occurs (Table 2). There is an urge to give a higher emphasis on the speci-
ficity of screening tests, particularly for universal and population-based screening, to
sensitize the general public and health professionals that overdiagnosis occurs more fre-
quently with screening, and to inform them about the potential implications of
Table 2 Key messages
• Overdiagnosis is the diagnosis of a condition that is not associated with a substantial health hazard; it causes
overtreatment.
• Screening is a major cause of overdiagnosis.
• Patients and physicians should be informed about risk of overdiagnosis associated with screening. Targeted
screening, active surveillance, and prognosis estimation allow prevention of overdiagnosis and of
overtreatment.
• Research is needed to assess the public health burden of overdiagnosis due to screening activity.
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overdiagnosis. Research is also needed to assess the public health burden and implica-
tions of overdiagnosis due to screening activity.
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